Status:
COMPLETED
Nicotinic Receptors and Schizophrenia
Lead Sponsor:
VA Office of Research and Development
Conditions:
Schizophrenia
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
The study determines if a new preparation of a drug designed to treat schizophrenia is more slowly released into the body.
Detailed Description
3-2,4 dimethoxybenzylidene will be compounded with a methyallose compound in doses of 150 and 300 mg. The capsules will be administered singly and eventually bid to determine if sustained blood levels...
Eligibility Criteria
Inclusion
- Healthy volunteers: males and females who are incapable of pregnancy
Exclusion
- Medical illnesses requiring acute treatment
- History of seizures
- Substance abuse including nicotine
Key Trial Info
Start Date :
January 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2014
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT00952393
Start Date
January 1 2010
End Date
October 1 2014
Last Update
February 5 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
VA Eastern Colorado Health Care System, Denver
Denver, Colorado, United States, 80220